UPDATE 4-Cell Therapeutics drug draws US FDA staff concerns
* FDA staff raise issues with safety, effectiveness
* Pixantrone to be reviewed by advisory panel Wednesday
* Company says drug works, side effects manageable
* Shares fall nearly 40 pct (Updates shares, adds details on Novartis option)











